Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachelle W Johnson

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Oncogene|July 11, 2021
HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancerMiranda E Clements, Lauren Holtslander, Courtney Edwards, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 9, 2019
Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone diseaseJoseph P Vanderburgh, Kristin A Kwakwa, Thomas A Werfel, et al.
Cancer Research|December 30, 2010
TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signalingRachelle W Johnson, Mai P Nguyen, Susan S Padalecki, et al.
Connective Tissue Research|November 22, 2025
The nuclear localization sequence and C-terminus of parathyroid hormone-related protein regulate chondrocyte development in epiphyseal growth cartilageWaleed J Hashmi, Nathan K Hoggard, Noriko Kantake, et al.
The Journal of Biological Chemistry|August 20, 2016
Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone MassEmma C Walker, Rachelle W Johnson, Yifang Hu, et al.
JBMR Plus|April 19, 2021
EphA2 Is a Clinically Relevant Target for Breast Cancer Bone Metastatic DiseaseDavid B Vaught, Alyssa R Merkel, Conor C Lynch, et al.
Nature Cell Biology|September 20, 2016
Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrowRachelle W Johnson, Elizabeth C Finger, Monica M Olcina, et al.
Nature Cell Biology|October 28, 2016
Erratum: Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrowRachelle W Johnson, Elizabeth C Finger, Monica M Olcina, et al.
Nature Communications|October 11, 2017
Bone corticalization requires local SOCS3 activity and is promoted by androgen action via interleukin-6Dae-Chul Cho, Holly J Brennan, Rachelle W Johnson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 9, 2026
Programmed cell death ligand 1 (PD-L1) inhibition in tumor naïve mice is bone-sparing throughout the lifespanMadeline B Searcy, Gwenyth J Joseph, Jeremy F Kane, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Oncogene|July 11, 2021
HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancerMiranda E Clements, Lauren Holtslander, Courtney Edwards, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 9, 2019
Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone diseaseJoseph P Vanderburgh, Kristin A Kwakwa, Thomas A Werfel, et al.
Cancer Research|December 30, 2010
TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signalingRachelle W Johnson, Mai P Nguyen, Susan S Padalecki, et al.
Connective Tissue Research|November 22, 2025
The nuclear localization sequence and C-terminus of parathyroid hormone-related protein regulate chondrocyte development in epiphyseal growth cartilageWaleed J Hashmi, Nathan K Hoggard, Noriko Kantake, et al.
The Journal of Biological Chemistry|August 20, 2016
Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone MassEmma C Walker, Rachelle W Johnson, Yifang Hu, et al.
JBMR Plus|April 19, 2021
EphA2 Is a Clinically Relevant Target for Breast Cancer Bone Metastatic DiseaseDavid B Vaught, Alyssa R Merkel, Conor C Lynch, et al.
Nature Cell Biology|September 20, 2016
Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrowRachelle W Johnson, Elizabeth C Finger, Monica M Olcina, et al.
Nature Cell Biology|October 28, 2016
Erratum: Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrowRachelle W Johnson, Elizabeth C Finger, Monica M Olcina, et al.
Nature Communications|October 11, 2017
Bone corticalization requires local SOCS3 activity and is promoted by androgen action via interleukin-6Dae-Chul Cho, Holly J Brennan, Rachelle W Johnson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 9, 2026
Programmed cell death ligand 1 (PD-L1) inhibition in tumor naïve mice is bone-sparing throughout the lifespanMadeline B Searcy, Gwenyth J Joseph, Jeremy F Kane, et al.
Pageof 6